Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma

NCT00680225 is registered in ClinicalTrials.gov with New England Retina Associates as lead sponsor.

NCT NCT00680225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00680225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma
Lead sponsor
New England Retina Associates
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2007
Completion date
July 31, 2012
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal melanoma